AstraZeneca Signs an Agreement with Sobi to Buy its Priority Review Voucher for $95M
Shots:
- Sobi to sell its US FDA’s Priority Review Voucher to AstraZeneca for $95M in cash. The PRV was acquired as part of the acquisition of the emapalumab from Novimmune in July’2019
- The PRV entitles the holder to FDA priority review of a single NDA or BLA which reduces the target review time leading to an expedited approval. The transaction is subject to clearance under HSR Antitrust Improvements Act
- Emapalumab (marketed as Gamifant) is an anti-interferon-gamma (IFN-ɣ) mAb used for the treatment of hemophagocytic lymphohistiocytosis and has received FDA’s ODD- BT- rare pediatric disease designation and EMA’s PRIME designation
Source 1- Source 2 to read full press release/ article
Ref: AstraZeneca- Sobi | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com